FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

The FDA's approval of Bristol Myers Squibb's Zenbexus™ marks the debut of a new drug class for treating multiple myeloma. The drug's approval comes as Bristol Myers Squibb faces financial strain from generic competition. The company's portfolio has been battered by generics, and the approval of Zenbexus™ is a strategic move to bolster its offerings. The approval of Zenbexus™ is significant because it represents the first CELMoD therapy approved by the FDA.

The drug is indicated for use in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for patients with multiple myeloma, as early as first relapse. The approval was granted under the FDA's accelerated approval program, which allows for faster review and approval of drugs that treat serious conditions and fill an unmet medical need. The approval of Zenbexus™ has been widely reported by industry outlets, including BioSpace, Fierce Pharma, and STAT. Reuters and Bristol Myers Squibb also covered the news.

The drug's approval is a notable development in the treatment of multiple myeloma, a type of blood cancer. However, the financial impact of Zenbexus™ on Bristol Myers Squibb remains uncertain, as the company continues to navigate the challenges posed by generic competition.